Martiney M J, Levy L S, Lenz J
Department of Molecular Genetics, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
J Virol. 1999 Mar;73(3):2143-52. doi: 10.1128/JVI.73.3.2143-2152.1999.
The transcriptional enhancer of the lymphomagenic mouse retrovirus SL3 contains a binding site for the transcription factor core binding factor (CBF; also called AML1, PEBP2, and SEF1). The SL3 CBF binding site is called the core. It differs from the core of the weakly lymphomagenic mouse retrovirus Akv by one nucleotide (the sequences are TGTGGTTAA and TGTGGTCAA, respectively). A mutant virus called SAA that was identical to SL3 except that its core was mutated to the Akv sequence was only moderately attenuated for lymphomagenicity. In most SAA-infected mice, tumor proviruses contained either reversions of the original mutation or one of two novel core sequences. In 20% of the SAA-infected mice, tumor proviruses retained the original SAA/Akv core mutation but acquired one of two additional mutations (underlined), TGCGGTCAA or TGTGGTCTA, that generated core elements called So and T*, respectively. We tested whether the novel base changes in the So and T* cores were suppressor mutations. SL3 mutants that contained So or T* cores in place of the wild-type sequence were generated. These viruses induced T-cell lymphomas in mice more quickly than SAA. Therefore, the mutations in the So and T* cores are indeed second-site suppressor mutations. The suppressor mutations increased CBF binding in vitro and transcriptional activity of the viral long terminal repeats (LTRs) in T lymphocytes to levels comparable to those of SL3. Thus, CBF binding was increased by any of three different nucleotide changes within the sequence of the SAA core. Increased CBF binding resulted in increased LTR transcriptional activity in T cells and in increased viral lymphomagenicity.
致淋巴瘤小鼠逆转录病毒SL3的转录增强子含有转录因子核心结合因子(CBF;也称为AML1、PEBP2和SEF1)的结合位点。SL3的CBF结合位点称为核心。它与弱致淋巴瘤小鼠逆转录病毒Akv的核心在一个核苷酸上不同(序列分别为TGTGGTTAA和TGTGGTCAA)。一种名为SAA的突变病毒与SL3相同,只是其核心突变为Akv序列,其致淋巴瘤性仅中度减弱。在大多数感染SAA的小鼠中,肿瘤前病毒包含原始突变的回复突变或两个新核心序列之一。在20%感染SAA的小鼠中,肿瘤前病毒保留了原始的SAA/Akv核心突变,但获得了另外两个突变(下划线)之一,TGCGGTCAA或TGTGGTCTA,分别产生了称为So和T的核心元件。我们测试了So和T核心中的新碱基变化是否为抑制突变。产生了包含So或T核心代替野生型序列的SL3突变体。这些病毒在小鼠中诱导T细胞淋巴瘤的速度比SAA更快。因此,So和T核心中的突变确实是第二位点抑制突变。抑制突变在体外增加了CBF结合以及病毒长末端重复序列(LTR)在T淋巴细胞中的转录活性,使其达到与SL3相当的水平。因此,SAA核心序列内的三种不同核苷酸变化中的任何一种都增加了CBF结合。CBF结合增加导致T细胞中LTR转录活性增加以及病毒致淋巴瘤性增加。